Nano-X Imaging (NNOX) director buys 50,000 shares, holds options
Rhea-AI Filing Summary
Nano-X Imaging Ltd. director Suesskind Dan S reported open-market purchases of a total of 50,000 Ordinary Shares on July 27, 2026, in two blocks of 25,000 shares at $0.94 and $0.92 per share. The Rule 10b5-1 checkbox was not marked for these transactions.
He also reports outstanding stock options to acquire 12,505 shares at $64.6100, 50,000 shares at $17.6300, and 10,000 shares at $11.5200, with expirations between 2031 and 2033, plus time-vested RSUs granted in 2024 and 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 50,000 shares
Net Buy
7 txns
Insider
Suesskind Dan S
Role
Director
Bought
50,000 shs ($47K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Ordinary Shares | 25,000 | $0.94 | $24K |
| Purchase | Ordinary Shares | 25,000 | $0.92 | $23K |
| holding | Stock Option (right to buy ordinary shares) F1, F4 | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) F1, F5 | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) F1, F6 | -- | -- | -- |
| holding | Ordinary Shares F1, F2 | -- | -- | -- |
| holding | Ordinary Shares F1, F3 | -- | -- | -- |
Holdings After Transaction:
Ordinary Shares — 75,336 shares (Direct);
Stock Option (right to buy ordinary shares) — 72,505 shares (Direct)
Footnotes (6)
- F1. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
- F2. The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on December 10, 2024 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2027) all underlying shares will be issued to the Reporting Person.
- F3. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer on December 10, 2025 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2028) all underlying shares will be issued to the Reporting Person.
- F4. The options reported in this row were granted to the Reporting Person by the Issuer on February 9, 2021 and are fully vested and exercisable as of the date of this report.
- F5. The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and are fully vested and exercisable as of the date of this report.
- F6. The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable on the four-year anniversary of that grant approval date (August 14, 2027).
Key Figures
Shares purchased at $0.9400: 25,000 shares at $0.9400 per share
Shares purchased at $0.9200: 25,000 shares at $0.9200 per share
Total shares purchased: 50,000 Ordinary Shares
+3 more
6 metrics
Shares purchased at $0.9400
25,000 shares at $0.9400 per share
Open-market purchase of Ordinary Shares on July 27, 2026
Shares purchased at $0.9200
25,000 shares at $0.9200 per share
Second open-market purchase of Ordinary Shares on July 27, 2026
Total shares purchased
50,000 Ordinary Shares
Aggregate net-buy Ordinary Share purchases reported for July 27, 2026
Option exercise price 2031 grant
$64.6100 per share
Stock option over 12,505 underlying Ordinary Shares expiring February 9, 2031
Option exercise price 2032 grant
$17.6300 per share
Stock option over 50,000 underlying Ordinary Shares expiring December 28, 2032
Option exercise price 2033 grant
$11.5200 per share
Stock option over 10,000 underlying Ordinary Shares expiring December 31, 2033
Key Terms
restricted share units ("RSUs"), fully vested and exercisable, three-year anniversary of the grant date, equal quarterly installments
4 terms
fully vested and exercisable financial
"options reported in this row were granted ... and are fully vested and exercisable as of the date"
three-year anniversary of the grant date financial
"such that by the three-year anniversary of the grant date ... all underlying shares will be issued"
equal quarterly installments financial
"vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted)"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider buying did Nano-X Imaging (NNOX) disclose for Suesskind Dan S?
Suesskind Dan S, a director of Nano-X Imaging, reported purchasing a total of 50,000 Ordinary Shares on July 27, 2026, in two separate 25,000-share open-market transactions at $0.94 and $0.92 per share, increasing his direct equity exposure.
What stock options does the Nano-X Imaging (NNOX) director hold after these transactions?
He holds stock options over 12,505 shares at $64.6100 expiring February 9, 2031, 50,000 shares at $17.6300 expiring December 28, 2032, and 10,000 shares at $11.5200 expiring December 31, 2033, all reported as directly owned awards.
What RSU awards are reported for the Nano-X Imaging (NNOX) director?
Footnotes describe RSUs granted on December 10, 2024 and December 10, 2025. Each grant vests in twelve equal quarterly installments of 8.33% so that all underlying shares are issued by the respective three-year anniversaries in December 2027 and December 2028.
What is Suesskind Dan S’s role at Nano-X Imaging (NNOX)?
Suesskind Dan S is reported as a director of Nano-X Imaging Ltd., with no officer position and not flagged as a more-than-10% shareholder. The reported Ordinary Share purchases and equity awards reflect his personal director-level holdings.